In today's volatile market landscape, geopolitical tensions and sector-specific dynamics are intricately intertwined, shaping investor sentiment and corporate strategies. The escalation of US-Iran tensions has cast a shadow over global markets, with oil prices experiencing fluctuations as investors weigh the potential for conflict against diplomatic de-escalation signals. This geopolitical uncertainty is compounded by persistent inflationary pressures, prompting the Federal Reserve to signal a likely rate hike in December, further influencing market dynamics. Amidst this backdrop, the airline sector is navigating a complex environment. Rising fuel costs, driven by geopolitical tensions, are squeezing margins, while demand recovery remains uneven. Airlines are grappling with capacity adjustments and cost management strategies to maintain profitability in a challenging macroeconomic climate. The semiconductor industry, led by giants like Nvidia, is at a crossroads. Nvidia's recent scandal involving its CEO, Jensen Huang, and allegations of espionage has introduced a layer of uncertainty. While the company's stock has shown resilience, the scandal raises questions about leadership stability and national security implications, particularly concerning Nvidia's dealings with China. This situation underscores the broader challenges facing the semiconductor sector, including supply chain disruptions and geopolitical risks, which are critical as the industry underpins the burgeoning AI and data center markets. Energy companies are also feeling the impact of geopolitical tensions, with oil prices serving as a barometer for investor sentiment. The sector is closely monitoring developments in the Middle East, as any escalation could lead to supply disruptions, further inflating prices. However, the potential for diplomatic resolutions offers a counterbalance, with investors remaining cautious yet hopeful for stability. Corporate developments are further complicating the market narrative. Nvidia's internal investigation into the espionage allegations highlights the delicate balance between corporate governance and geopolitical considerations. The company's ability to navigate this scandal will be pivotal in maintaining investor confidence and securing its position in the global semiconductor market. In the broader corporate landscape, companies are bracing for increased scrutiny from a Democratic-led Congress, particularly those involved in AI and data center expansions. This political shift could lead to regulatory challenges and impact corporate strategies, especially for firms like Anthropic, which is preparing for a significant IPO amidst market volatility. As the market digests these multifaceted developments, investors are closely watching inflation data and corporate earnings reports for further insights. The interplay between macroeconomic factors and corporate performance will be crucial in determining market direction in the coming weeks. With geopolitical tensions, sector-specific challenges, and corporate governance issues at the forefront, the market remains on edge, reflecting the complex and interconnected nature of today's global economy.
Companies Reporting Earnings Today
| Symbol | Price | Change | MarketCap |
|---|---|---|---|
| PBR | 18.35000 | -0.97% | 118254125055 |
| PBR-A | 16.31000 | -0.55% | 110674461889 |
| BPYPN | 13.69000 | 0.37% | 95924142954 |
| TDG | 1218.85000 | 1.82% | 67373792496 |
| SE | 77.96000 | 2.94% | 45891209819 |
| VOD | 15.69000 | 0.71% | 36351595987 |
| ALC | 75.14000 | 0.27% | 36322676000 |
| EC | 15.61000 | 0.39% | 32091580401 |
| VG | 11.80000 | 2.39% | 29501097978 |
| CRWV | 48.98000 | 5.56% | 27014260709 |
| VIV | 11.61000 | 1.57% | 18550514483 |
| EMBJ | 77.07000 | 4.04% | 14143514306 |
| ONON | 37.53000 | 0.46% | 12361350863 |
| FRHC | 174.60000 | -2.38% | 11137326484 |
| KT | 19.17000 | 1.21% | 9367917406 |
| BPYPO | 14.94000 | 0.20% | 6673720111 |
| BPYPP | 15.30000 | -1.31% | 6418858220 |
| SRRK | 51.55000 | 9.82% | 6278016750 |
| MANE | 143.95000 | 3.73% | 6014250577 |
| ATH-PE | 24.51000 | 0.66% | 4995138000 |
| ATAT | 35.73000 | -0.50% | 4937383922 |
| MRCY | 79.62000 | 8.25% | 4845958717 |
| ALH | 24.04000 | 6.37% | 4778889868 |
| TEO | 10.26000 | 2.91% | 4671263078 |
| LEGN | 24.29000 | 3.80% | 4492269939 |
| RGTI | 12.98000 | 10.47% | 4332318336 |
| RGTIW | 3.35000 | 32.41% | 4332318336 |
| QBTS | 11.47000 | 7.40% | 4317887602 |
| LQDA | 47.87000 | 7.82% | 4284790612 |
| FLY | 24.31000 | 17.10% | 4069606920 |
| IAC | 46.15000 | -0.60% | 3432982940 |
| ATH-PB | 16.76000 | -0.83% | 3415688000 |
| REZI | 20.05000 | 3.35% | 3044539929 |
| WIX | 69.75000 | -8.33% | 2919003392 |
| DAC | 147.16000 | -0.64% | 2678841776 |
| SEAL-PA | 25.29000 | 0.36% | 2526453600 |
| IMNM | 19.36000 | 3.47% | 2284538080 |
| SEAL-PB | 25.19000 | 0.04% | 2191681140 |
| ATRO | 58.99000 | 7.82% | 2130010920 |
| STUB | 5.85000 | -4.72% | 2090438801 |
| DRVN | 12.26000 | 3.11% | 2022652544 |
| SONO | 17.01000 | 3.66% | 2012180940 |
| COAG | 42.81000 | -12.67% | 1999745686 |
| ETOR | 23.32000 | 1.52% | 1889156115 |
| HSAI | 14.31000 | -0.14% | 1869506525 |
| BRSL | 10.01000 | 1.11% | 1841839920 |
| SBH | 19.49000 | 6.44% | 1824698627 |
| AZTA | 40.95000 | 4.57% | 1793953980 |
| IMOS | 47.95000 | 9.52% | 1678209243 |
| ATEX | 80.78000 | 8.63% | 1584078513 |
| BTDR | 6.61000 | 9.89% | 1502997155 |
| AMPX | 9.52000 | 9.17% | 1390687407 |
| GO | 13.87000 | 6.77% | 1374301904 |
| AMPX-WT | 2.56000 | 21.90% | 1359877678 |
| KARD | 15.18000 | -2.19% | 1356167857 |
| LMRI | 13.97000 | 4.02% | 1342167415 |
| ELE | 16.82000 | 5.52% | 1286245651 |
| NN | 8.92000 | 3.60% | 1217017496 |
| AMBQ | 45.77000 | 18.70% | 1106926213 |
| BV | 11.85000 | 1.54% | 1097310000 |
| SKYH | 10.89000 | 5.93% | 888945320 |
| TBPH | 17.03000 | 0.00% | 884176381 |
| EVLV | 4.76000 | 4.39% | 856187912 |
| LWLG | 4.91000 | 12.49% | 756959970 |
| HQ | 13.81000 | 20.72% | 745354425 |
| ABUS | 3.72000 | 1.78% | 736953353 |
| LAR | 4.44000 | 4.47% | 728604000 |
| CGEM | 11.73000 | 3.71% | 720902880 |
| ACHV | 6.78000 | 0.89% | 697675560 |
| FDMT | 12.48000 | 1.88% | 689447616 |
| ANGX | 3.69000 | 8.85% | 689130865 |
| KURA | 7.57000 | 4.13% | 673431742 |
| ELMT | 21.99000 | 12.08% | 669804339 |
| NRGV | 3.62000 | 11.73% | 658259243 |
| CRESY | 9.26000 | 1.48% | 656767315 |
| JBI | 4.76000 | 2.59% | 649434360 |
| KOPN | 3.38000 | 11.37% | 628250740 |
| CAPR | 9.85000 | 9.44% | 570432146 |
| SATL | 3.96500 | 13.94% | 567617505 |
| SATLW | 0.06500 | 1.56% | 567617505 |
| GILT | 7.58000 | 5.42% | 563269800 |
| LPTH | 8.01000 | 13.46% | 561410487 |
| HYLN | 3.14000 | 5.02% | 560794580 |
| AII | 27.76000 | 3.01% | 543961836 |
| MCFT | 20.50000 | 0.69% | 496590627 |
| EPRX | 7.42000 | 7.69% | 490264428 |
| FOSL | 8.06000 | 3.20% | 476652699 |
| MASS | 11.51000 | 9.00% | 475750887 |
| BWAY | 11.64000 | 4.39% | 456555720 |
| CARL | 16.05000 | 10.54% | 438209009 |
| GLOP-PB | 26.10000 | -0.27% | 418555286 |
| THM | 1.59000 | 3.33% | 416002830 |
| CLFD | 30.55000 | 6.71% | 414991200 |
| SKYH-WT | 0.24000 | 27.05% | 385340721 |
| WYFI | 9.57000 | 7.77% | 371776489 |
| SPIR | 9.46000 | 9.36% | 370027900 |
| WSBF | 20.51000 | 3.27% | 368708844 |
| GEVO | 1.47000 | 5.76% | 363438390 |
| OIG | 9.25000 | 3.12% | 361649026 |
| AUTL | 1.32000 | 3.12% | 351334553 |
| IRD | 4.20000 | 0.48% | 349422360 |
| ARTNA | 33.72000 | -1.95% | 348230520 |
| CDZIP | 19.28000 | -1.83% | 327968841 |
| LAND | 6.98000 | -0.57% | 301093280 |
| RCKT | 2.53000 | 6.08% | 277729730 |
| FBLA | 16.50000 | -2.14% | 263144937 |
| IMSR | 3.00000 | 5.63% | 248155701 |
| SUJA | 10.42000 | 5.36% | 247878254 |
| AVNW | 19.13000 | 8.32% | 245985611 |
| CDR-PC | 16.66000 | -0.54% | 228544696 |
| REFI | 8.86000 | 0.68% | 227003345 |
| ELMD | 27.06000 | -0.40% | 224248385 |
| RDNW | 5.59000 | 2.76% | 217792482 |
| BGS | 2.66000 | 6.19% | 216193285 |
| CURR | 1.90000 | 0.53% | 213335572 |
| PLX | 2.57000 | 1.18% | 207069120 |
| VELO | 6.23000 | 11.65% | 200288893 |
| BRCB | 11.10000 | 3.35% | 200000044 |
| TLSI | 3.22000 | -0.92% | 198270212 |
| UPB | 3.58000 | 10.84% | 196080323 |
| FIRY | 11.85000 | 3.22% | 184948365 |
| IMPPP | 25.60000 | 0.20% | 181600922 |
| IVVD | 0.59620 | 5.90% | 175735164 |
| PDYN | 3.54000 | 17.22% | 174658325 |
| XGN | 7.10000 | 22.20% | 171999630 |
| FUFUW | 0.09290 | 0.00% | 168820168 |
| IMPP | 4.45000 | -1.33% | 167281806 |
| EML | 27.25000 | 3.89% | 163978510 |
| REA | 7.99000 | -0.87% | 163893916 |
| TONX | 2.95000 | 7.66% | 162462400 |
| WENC | 10.05500 | 0.35% | 161378557 |
| SION | 3.57000 | 8.84% | 161186678 |
| NCMI | 1.66000 | 5.06% | 156156864 |
| QUIK | 8.47000 | 5.28% | 155150919 |
| KRMD | 3.23000 | 4.53% | 148363590 |
| YARW | 15.79000 | 1.22% | 146915860 |
| GUNN | 8.49000 | 4.69% | 145760234 |
| EPM | 3.54000 | 1.72% | 142209680 |
| HYNE | 18.24000 | 0.33% | 136148759 |
| MXCT | 1.30000 | 3.17% | 134168073 |
| DPRO | 3.35000 | 4.85% | 131128233 |
| HUMA | 0.45520 | 1.56% | 126453697 |
| AP | 6.00000 | 1.87% | 123951600 |
| ZNTL | 1.74000 | 1.16% | 123864246 |
| FAC | 4.47000 | 5.18% | 123372000 |
| STXS | 1.14000 | 4.59% | 114230280 |
| HSDT | 1.92000 | -0.52% | 112102416 |
| SSTI | 8.32000 | -0.24% | 110160960 |
| BDTX | 1.86000 | 7.20% | 106581300 |
| INO | 1.51000 | 24.28% | 104328854 |
| MRDN | 8.20000 | -5.53% | 103656708 |
| DAVA | 1.69000 | -3.43% | 98365524 |
| BEEP | 2.37000 | -1.25% | 97881000 |
| SWMR | 8.97000 | 26.34% | 97391892 |
| SUNS | 6.92500 | 2.44% | 93597268 |
| SEER | 1.68000 | 3.07% | 93024960 |
| GRWG | 1.57000 | 4.67% | 92505185 |
| NMRA | 0.48590 | -3.46% | 91298618 |
| USIO | 3.07000 | 3.72% | 87480878 |
| FRNM | 10.57000 | 3.83% | 86222048 |
| JRSH | 6.57000 | 7.70% | 83438606 |
| CAN | 0.20210 | 8.71% | 80770757 |
| CPIX | 5.37000 | 2.87% | 80459247 |
| HMR | 1.33000 | 5.56% | 78459356 |
| KULR | 1.63000 | 10.51% | 75437215 |
| LPA | 2.35000 | 1.73% | 74491710 |
| MWC | 1.17000 | 4.46% | 69520714 |
| LNSR | 5.46000 | 0.18% | 67080823 |
| GOSS | 10.64500 | 8.96% | 65047124 |
| EVTL | 0.38000 | -6.08% | 64083553 |
| PODC | 2.06000 | 6.19% | 62320554 |
| CRDF | 0.80070 | 0.68% | 62290617 |
| FJET | 1.09000 | 33.24% | 59945659 |
| XLO | 9.00000 | 4.41% | 59221377 |
| DGNX | 1.15000 | -2.54% | 57649649 |
| APT | 5.55000 | 2.40% | 56644510 |
| BOLD | 2.46000 | 0.00% | 55960046 |
| KLRS | 2.30000 | -4.96% | 54751456 |
| AIRG | 4.31000 | 6.68% | 54632612 |
| MCHX | 1.30000 | -1.52% | 51587510 |
| BTCS | 0.96220 | 3.80% | 51102731 |
| LINK | 3.18000 | 2.58% | 50095812 |
| DWSN | 1.60000 | -2.44% | 49688960 |
| GENK | 1.42000 | 11.81% | 49556499 |
| MDAI | 1.53000 | 2.68% | 49242897 |
| HOWL | 1.01000 | 0.00% | 49085091 |
| GROV | 1.10000 | 0.92% | 46971151 |
| HQWWW | 5.85000 | 19.88% | 46585013 |
| GANX | 1.09000 | 5.83% | 46492901 |
| ELOX | 13.51000 | 8.60% | 46424602 |
| BMEA | 0.59500 | 4.98% | 43018167 |
| SEATW | 0.01700 | 0.00% | 42411905 |
| SCWO | 2.38000 | -2.46% | 41946905 |
| HBIO | 9.09000 | 8.73% | 41380407 |
| ZENA | 0.66460 | 4.02% | 41096903 |
| PRPO | 22.20000 | 19.23% | 39742174 |
| XTNT | 0.27900 | -3.59% | 39140341 |
| TELA | 0.86460 | 5.44% | 39030984 |
| RANI | 0.57430 | 5.03% | 37513276 |
| NPT | 1.61000 | -13.90% | 35717850 |
| VRM | 6.76500 | 3.60% | 35410418 |
| QTI | 2.29000 | 12.81% | 33517640 |
| BODI | 4.51000 | 6.12% | 32854159 |
| COHN | 10.05000 | -1.37% | 32451149 |
| HHS | 4.00000 | 1.01% | 29816960 |
| EFOI | 4.39500 | 8.77% | 27992731 |
| MGX | 0.72170 | 1.73% | 27263735 |
| PETS | 1.25000 | 2.46% | 27098625 |
| AIFC | 0.19250 | 12.11% | 26918528 |
| EVEX-WT | 0.00980 | 0.00% | 26173544 |
| FLD | 0.46060 | 3.27% | 25272758 |
| FACWW | 0.75000 | 9.47% | 20700000 |
| UONEK | 3.58000 | 0.56% | 20620743 |
| CIRC | 0.20400 | 6.25% | 18351840 |
| JSPR | 16.37000 | -2.91% | 18156818 |
| MNDO | 0.87000 | 0.69% | 17724336 |
| SNWV | 1.85000 | -15.53% | 15914272 |
| AHT | 2.37000 | 0.00% | 15333459 |
| IPM | 1.69000 | 4.53% | 15270382 |
| QNTM | 2.23000 | 5.94% | 14337903 |
| MDAIW | 0.44000 | 0.11% | 14161356 |
| NCT | 0.86090 | -17.21% | 13789474 |
| BNGO | 1.16000 | 0.87% | 13661320 |
| ACCS | 3.37000 | -1.03% | 12898014 |
| AHT-PD | 3.68100 | -3.89% | 12880691 |
| DLPN | 0.98500 | 5.73% | 12838293 |
| AHT-PF | 3.20000 | 0.71% | 12733507 |
| PLUR | 1.18000 | -4.48% | 12731610 |
| AHT-PI | 3.40000 | -1.73% | 12661008 |
| AHT-PH | 3.38000 | 2.42% | 12406726 |
| AHT-PG | 3.33000 | -0.89% | 12222945 |
| CLRB | 1.28000 | 2.40% | 12098698 |
| BBGI | 5.56000 | -5.76% | 11413290 |
| PASG | 3.43000 | -13.82% | 11037088 |
| UONE | 3.95010 | -2.71% | 10086829 |
| BIRD | 1.35000 | 3.05% | 8471016 |
| SUNE | 2.03000 | -0.98% | 6765308 |
| KPRX | 1.51000 | 4.86% | 6680829 |
| LGVN | 2.01000 | 11.05% | 6117029 |
| SNES | 1.14000 | 3.17% | 6045906 |
| PCSA | 1.95000 | 1.04% | 5456568 |
| DSS | 0.49510 | 0.79% | 4972042 |
| PULM | 1.35500 | -1.81% | 4948846 |
| TWAV | 1.27000 | -2.31% | 4924068 |
| CALC | 1.51500 | 11.40% | 4770406 |
| XBIO | 1.79750 | -3.91% | 4211866 |
| SBFMW | 0.02550 | 0.00% | 4182323 |
| ADXN | 2.79000 | -3.63% | 3437090 |
| KALA | 0.17730 | 13.73% | 3428947 |
| SQFTP | 6.30000 | -6.67% | 2997515 |
| XPON | 2.58000 | 5.31% | 2459233 |
| CODX | 0.31900 | 24.22% | 2376137 |
| CAPS | 2.10010 | 10.53% | 1939724 |
| NXGL | 3.64500 | 1.25% | 1776511 |
| FLDDW | 0.05015 | 0.30% | 1479974 |
| EZRA | 2.61000 | 23.70% | 1450544 |
| SQFTW | 0.01090 | 3.81% | 1389803 |
| SQFT | 0.82400 | 3.00% | 1181970 |
| IMSRW | 0.55000 | 8.93% | 570900 |
| KUST | 3.42000 | 8.23% | 429614 |
| CDR-PB | 17.50000 | 0.29% | 401240 |
| RKDA | 0.16580 | 2.98% | 256545 |
| CTNT | 1.67000 | 6.37% | 32909 |
6-K/8-K Form Update
JRSH
Jerash Holdings (US), Inc. reported a 19.8% revenue increase to $50.3 million for the fiscal 2027 second quarter, ending September 30, 2026. Gross profit surged 45.4% to $9.1 million, with gross margin expanding to 18.2% from 15.0%. Operating income nearly tripled to $3.1 million, and net income rose to $2.2 million. The company anticipates third-quarter revenue of $49-$51 million, up 17-22%, with gross margins expected at 16-17% due to higher transportation costs. Production facilities are fully booked through June 2027, with a new factory set to boost capacity by 15-20% by September 2027.
TYRA
Tyra Biosciences, Inc. reported third-quarter 2026 financial results, highlighting a $400 million financing to advance dabogratinib's development across multiple programs. The company achieved a 79% overall response rate in Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade invasive bladder cancer patients. With $700.5 million in cash, cash equivalents, and marketable securities as of September 30, 2026, Tyra expects to fund operations through 2030.
CRMT
America's Car-Mart, Inc. secured compliance with its credit obligations by amending its Credit and Guaranty Agreement with Silver Point Finance, LLC, as Administrative Agent and Collateral Agent, and the lenders. The amendment, effective from October 30, 2025, to November 12, 2026, suspends certain events of default, including liquidity and collateral coverage requirements. The filing, signed by CFO Marie Persichetti on November 10, 2026, confirms adherence to the Securities Exchange Act of 1934.
PEPG
PepGen Inc. reported positive topline results from its Phase 2 FREEDOM2-DM1 trial, demonstrating significant splicing correction in patients with myotonic dystrophy type 1. The company's cash, cash equivalents, and marketable securities totaled $104.8 million as of September 30, 2026, expected to fund operations through 2028. Research and development expenses increased to $14.5 million, while the net loss for the quarter was $19.4 million, or $(0.28) per share.
ASTS
Rakuten Group, Inc. and AST SpaceMobile, Inc. established Rakuten AST, Inc., a joint venture to build a direct-to-device communications network in Japan using low Earth orbit satellites. The Ministry of Internal Affairs and Communications selected their proposal for the "J-LEO: Japan Low Earth Orbit Satellite Communications Project," with Rakuten AST expected to receive up to 148 billion yen in support over three years. The venture aims to deploy a satellite network by March 2029, enhancing Japan's communications infrastructure, especially during emergencies.
MCFT
MasterCraft Boat Holdings, Inc. reported a robust financial performance for the first three months of its transition period, ending October 4, 2026, with net sales reaching $154.1 million, a 123.4% increase year-over-year. The surge was primarily driven by the Marine Products Transaction, higher unit volumes, and favorable pricing in key segments. Adjusted Net Income rose to $12.2 million, or $0.50 per diluted share, up from $4.7 million, or $0.29 per diluted share, in the prior year, while Adjusted EBITDA increased by $13.1 million to $20.1 million. The company projects consolidated net sales for the transition period to be between $293 million and $297 million, with Adjusted EBITDA expected between $32 million and $34 million, and Adjusted Earnings per share between $0.75 and $0.80, maintaining capital expenditures around $9 million.
XGN
Exagen Inc. reported third-quarter financial results for the period ending September 30, 2026, with revenue growing 7% to $18.4 million and year-to-date revenue up 11%. The company reduced its net loss by 12% and improved its adjusted EBITDA loss by over 30%, ending the quarter with $28.1 million in cash and cash equivalents. Exagen's trailing-twelve-month average selling price per test increased by $10 to $451, and it reiterated full-year revenue guidance of $72 million to $75 million.
ABUS
Arbutus Biopharma Corporation returned $230 million to shareholders through a modified "Dutch Auction" tender offer, purchasing 46 million shares for cancellation. The company lifted the clinical hold on its oral PD-L1 inhibitor, AB-101, following a successful Phase 1 trial. Additionally, Arbutus filed lawsuits in Japan and amended a Canadian lawsuit against Pfizer and BioNTech, asserting infringement of newly issued LNP patents, seeking monetary relief and injunctions.
VREOD
Vireo Growth Inc. reported its financial results for the quarter ending September 30, 2026, and filed a registration statement on Form S-4 effective November 2, 2026, in connection with a merger with Planet 13. The company disclosed pre-commencement communications under Rule 13e-4(c) of the Exchange Act and issued a definitive proxy statement/prospectus for the special meeting to vote on the merger. Forward-looking information in the report includes financial outlooks and future M&A strategy.
EFOI
Energy Focus, Inc. reported a significant surge in net sales for the third quarter ended September 30, 2026, reaching $4.8 million, a 481.2% increase from the same period in 2025, driven by a 2115.8% rise in commercial sales due to the expansion of its Uninterruptible Power Supply (UPS) business in Taiwan. Gross profit margin improved to 20.5% from 17.8% in the previous year and (6.8)% in the prior quarter, aided by higher commercial sales, a favorable product mix, and a $184,000 customs refund. Operating income rose to $0.5 million from a loss of $0.2 million in the third quarter of 2025, with net income reaching $0.5 million, or $0.08 per share, compared to a net loss of $0.2 million in the same quarter last year.
PDYNW
Palladyne AI Corp. reported record third-quarter 2026 results, with revenue surging 895% year-over-year to $8.6 million, driven by the expiration of warrants and contingent shares. The company raised the low end of its full-year 2026 revenue guidance to $25 million while maintaining the top end at $27 million. Despite a 24% decrease in backlog to $18.7 million, operating cash burn decreased sequentially due to strong revenue performance, though it remains elevated due to ongoing R&D and working capital investments.
OLMA
Olema Pharmaceuticals, Inc. reported third-quarter financial results for the period ending September 30, 2026, with cash, cash equivalents, and marketable securities rising to $413.8 million. The company faced a net loss of $73.6 million, up from $42.2 million in the same quarter of 2025, driven by increased patient enrollment in pivotal Phase 3 trials, expanded clinical programs, and higher personnel-related costs. GAAP research and development expenses surged to $67.6 million, reflecting intensified spending on clinical trials and infrastructure.
HUMAW
Humacyte, Inc. reported a 151% increase in Symvess revenue to $1.0 million in the third quarter of 2026, with October sales reaching $0.8 million, indicating strong commercial momentum. The company initiated its first-in-human clinical Phase 2a study of CTEV for CABG and plans to file a supplemental Biologics License Application (sBLA) for the ATEV in dialysis access with the FDA in November 2026. Additionally, Humacyte appointed key nephrologists as advisors and added industry veterans Scott Coward and Paul Kuznik to its Board of Directors.
IRD
Opus Genetics, Inc. reported its third-quarter financial results for the period ending September 30, 2026, and provided a corporate update. The company completed Cohort 2 dosing for the OPGx-BEST1 trial, with data expected in Q1 2027, and fully enrolled the OPGx-LCA5 Phase 3 trial, with dosing anticipated in Q4 2026. Additionally, the FDA cleared the IND for OPGx-RDH12, with Phase 1/2 trial dosing planned for Q4 2026, and approved phentolamine ophthalmic solution 0.75% for presbyopia, triggering a milestone payment. Opus Genetics' cash runway extends into 2029, supporting multiple clinical inflection points and opportunities for priority review vouchers. The company reported a net loss of $46.5 million, primarily due to increased R&D expenses and decreased license and collaborations revenue.
ENVA
Enova International, Inc. authorized a new $500 million share repurchase program, replacing its existing $400 million program set to expire in June 2027, with the new program running until June 2028. This largest repurchase initiative in Enova's history underscores the company's confidence in its business model and growth prospects, as highlighted by CFO Scott Cornelis. The repurchases will be executed in compliance with applicable securities laws, with the Board retaining discretion to adjust the program as needed.
HBIO
Harvard Bioscience completed a debt refinancing in December 2025, extending maturity through 2029 to unlock $3M in annual cash savings and enhance financial flexibility. The company is executing Project Viking to consolidate its manufacturing footprint, targeting $3M in adjusted EBITDA improvement in 2027 and $4M/year starting in 2028. Additionally, Harvard Bioscience is optimizing commercial operations with new sales leadership, aiming for 57-59% adjusted gross margin in FY26 and 3-5% growth.
VG
Venture Global, Inc. reported robust third-quarter 2026 financial results, with revenue reaching $4.8 billion, a 43% increase from Q3 2025, and net income surging to $2.5 billion, up 493% from the previous year. The company's Consolidated Adjusted EBITDA rose 69% to $2.6 billion, and it commenced commercial operations at Phase 1 of the Plaquemines Project, achieving rapid LNG sales. Venture Global also announced frame agreements for up to 16 new power islands, increased its EBITDA guidance to $10.0-$10.3 billion for 2026, and tightened its contracted cargos to 99% at a weighted average fee of $6.46/MMBtu.
BDTX
Black Diamond Therapeutics, Inc. reported a cash position of $102.0 million as of September 30, 2026, expected to fund operations into the second half of 2028. The company disclosed updated Phase 2 results for silevertinib in frontline non-small cell lung cancer (NSCLC) patients with EGFR non-classical mutations, showing an 86% CNS-ORR and a median progression-free survival of 15.0 months, double that of current EGFR TKIs. The FDA indicated a clear path to potential accelerated and full approval for silevertinib, contingent on CNS-ORR and systemic PFS evaluations.
CYCUW
Cycurion, Inc. has launched Habit, an AI-driven security operations center aimed at preemptively identifying threats. The platform learns normal patterns for identities, devices, and workloads, then targets deviations, integrating with existing tools or deploying its own agent. Habit offers 24/7 human oversight, offensive analysis, and unlimited incident response, marking Cycurion's shift to a predictive cybersecurity model.
IMRN
Immuron Limited engaged LifeSci Capital as its exclusive financial advisor to explore strategic initiatives aimed at maximizing shareholder value, including potential mergers, acquisitions, licensing, or other transactions. The company, known for its orally delivered targeted polyclonal antibodies, is focusing on enhancing its portfolio, which includes Travelan® for travelers' diarrhea and IMM-529 for recurrent Clostridioides difficile infection. Immuron's proprietary platform technology, based on polyclonal immunoglobulins from engineered hyper-immune bovine collostrum, supports the development of medicines for a broad range of infectious diseases.
CAN
Canaan Inc. reported unaudited third-quarter 2026 financial results with total revenue of US$14.5 million, near the upper end of guidance. Mining revenue decreased due to lower bitcoin prices and computing power, while the company announced a US$20 million share repurchase program under a US$100 million Board authorization. Canaan also reported a US$51.9 million fair value gain on cryptocurrency holdings, contributing to a GAAP net income of US$8.0 million, as it progresses in energy and computing infrastructure projects.
BRSYF
BrainsWay Ltd. reported third-quarter 2026 financial results with revenue of $18.1 million, a 34% increase from the previous year, and operating income rising 107% to $2.6 million. The company shipped 130 Deep TMS systems, a 44% year-over-year increase, expanding its installed base to approximately 2,080 systems. Remaining performance obligations grew 31% to about $85 million, with cash and equivalents totaling $63.4 million. BrainsWay anticipates full-year results to potentially exceed guidance, driven by broader reimbursement coverage and increased utilization.
CNL
Collective Mining Ltd. expanded the known extent of the Ramp Zone at the Apollo deposit in Colombia. The company's drilling program intersected mineralization below the base of the Mineral Resource, extending it to approximately 280 meters above sea level. With plans to commence construction of a 3-kilometer underground exploration adit this month, the adit is designed to intersect the high-grade portion of the Ramp Zone, enhancing exploration potential.
ARIS
Aris Mining Corporation updated its Segovia mineral reserve and resource estimates, demonstrating a 28% increase in contained gold reserves to 1.9 million ounces, with net growth of 418,000 ounces after accounting for mined ounces. The company's proven and probable mineral reserves also increased by 28%, while measured and indicated mineral resources rose by 8% to 3.9 million ounces. Gold grades improved significantly, with reserve grades increasing by 24% to 13.3 g/t Au and resource grades by 29% to 19.8 g/t Au.
TSMWF
Taiwan Semiconductor Manufacturing Company Limited (TSMC) reported a 14.7 percent increase in net revenue for October 2026, reaching NT$586.89 billion, and a 59.7 percent year-over-year rise. For the January-October 2026 period, TSMC's consolidated revenue grew 43.3 percent to NT$4,485.62 billion. The company also disclosed financial updates, including NT$35.42 billion in funds lent to others and NT$2.71 billion in outstanding endorsements and guarantees.
LAR
Lithium Argentina AG reported a net income of $12.968 billion for Q3 2026, reversing a $64.474 billion loss in the same period of 2025, driven by gains from financial instruments and the Cauchari-Olaroz Project. Total assets rose to $1.353.768 billion, with significant increases in cash, receivables, and investments, while liabilities grew to $497.223 billion. Equity attributable to shareholders increased to $856.545 billion, reflecting higher share capital and reserves.
WIX
Wix reported third-quarter 2023 results, with bookings of $573 million, up 11% year-over-year, and revenue of $570 million, up 13% year-over-year, driven by Base44's strong performance. Base44's annual recurring revenue (ARR) is nearing $250 million, supported by robust demand and increased marketing investments, with retention and renewal rates exceeding expectations. Non-GAAP gross margin improved to 69% in Q3, with expectations for further gains in the second half. Wix also launched Studio Two, an AI-powered platform for designers, and appointed Nir Zohar as Co-CEO alongside Avishai Abrahami.
IMOS
ChipMOS Technologies Inc. agreed to acquire machinery equipment and related accessories for NT$805,498 thousand from Advantest Taiwan Inc. The transaction, approved by President S.J. Cheng, took place between April 8 and November 10, 2026, and is intended for manufacturing purposes. The acquisition, exceeding NT$500 million, was executed without an appraisal report or dissenting opinions from directors, and no significant related-party transactions occurred in the past five years.
EMBJ
Embraer S.A. revised its 2026 guidance in a recent Form 6-K filing, reflecting evolving operating conditions and associated risks. The company now projects commercial aviation deliveries between 80-85 and executive aviation deliveries, with consolidated net revenues expected to range from $160-170 billion. Adjusted EBIT margin is anticipated to be 8.4%-8.6%, with free cash flow of $400 million or higher and a free cash flow margin of 10.0%-10.6%, superseding previous guidance.
BZUN
Baozun Inc. announced its unaudited financial results for the third quarter and nine months ended September 30, 2026, to be released on November 24, 2026, after Hong Kong market hours and before the U.S. market opens. The company's board, led by Chairman Vincent Wenbin Qiu, will review and approve these results during a meeting on the same day. Baozun's weighted voting rights structure, with Class A shares granting one vote and Class B shares ten votes each, poses potential risks for investors.
KEN
OPC Energy Ltd. reported a significant increase in consolidated EBITDA after proportionate consolidation, rising by 38% in the nine-month period and 54% in the three-month period compared to 2025, driven by higher energy margins, capacity prices, and holding rates in the U.S. and Israel. Adjusted net income and consolidated FFO surged by 114% and 45%, respectively, in the nine-month period, and 121% and 59%, respectively, in the three-month period. The company completed the Hadera expansion project with 850 megawatts capacity and is advancing the Ramat Beka solar project, expected to receive final payment in Q4 2026, while also expanding its electricity supply to data centers through a long-term PPA agreement in Israel.
Pre-Market Options Data
